|
nasdaq:grfs
|
16940
|
Apr 14th, 2024 12:00AM
|
Grifols
|
223K
|
10766
|
Open
|
|
Apr 13th, 2024 11:07PM
|
Apr 14th, 2024 11:05AM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 13th, 2024 12:00AM
|
Grifols
|
223K
|
10764
|
Open
|
|
Apr 12th, 2024 10:58PM
|
Apr 13th, 2024 11:33AM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 12th, 2024 12:00AM
|
Grifols
|
223K
|
10766
|
Open
|
|
Apr 11th, 2024 11:03PM
|
Apr 12th, 2024 08:28AM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 11th, 2024 12:00AM
|
Grifols
|
223K
|
10766
|
Open
|
|
Apr 10th, 2024 11:36PM
|
Apr 11th, 2024 11:12AM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 10th, 2024 12:00AM
|
Grifols
|
223K
|
10772
|
Open
|
|
Apr 9th, 2024 11:06PM
|
Apr 10th, 2024 05:21PM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 9th, 2024 12:00AM
|
Grifols
|
222K
|
10776
|
Open
|
|
Apr 8th, 2024 11:17PM
|
Apr 9th, 2024 10:02AM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 8th, 2024 12:00AM
|
Grifols
|
222K
|
10776
|
Open
|
|
Apr 7th, 2024 11:42PM
|
Apr 8th, 2024 07:00PM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 7th, 2024 12:00AM
|
Grifols
|
222K
|
10768
|
Open
|
|
Apr 6th, 2024 11:12PM
|
Apr 6th, 2024 11:12PM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 6th, 2024 12:00AM
|
Grifols
|
222K
|
10767
|
Open
|
|
Apr 5th, 2024 11:13PM
|
Apr 5th, 2024 11:13PM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|
|
nasdaq:grfs
|
16940
|
Apr 5th, 2024 12:00AM
|
Grifols
|
222K
|
10766
|
Open
|
|
Apr 4th, 2024 11:40PM
|
Apr 4th, 2024 11:40PM
|
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2023, Forbes has recognized Grifols as one of the “Best Employers for Women.”
To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
|
Open
|
Plasmapheresis, Plasma derived therapies, Diagnostics, Intravenous therapies, Clinical nutrition, Automate drug compounding , Drug inventory control, and Healthcare
|
Open
|
Parc Empresarial Can Sant Joan
|
Sant Cugat del Vallès
|
Barcelona
|
ES
|
08174
|
|
Grifols
|
|
|